KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC Breast Cancer Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me
